Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: per strandberg who wrote (2625)	11/4/1997 8:10:00 PM
From: John Metcalf	Respond to of 6136

Per, do you know if this data is from the mouse and rat studies reported in April of '95? AG 3340 has since completed a Phase I study in Edinburgh in healthy volunteers. Bio-availability was demonstrated at concentrations which reduced tumors in animals. In June of 1997, AGPH received FDA clearance for a US human trial. The results that four of six mice were tumor-free is the same data reported almost three years ago. As David S. might say, their recoveries were confirmed by autopsy. I look forward to seeing results in humans. We've had the rodent studies for a long time.

To: per strandberg who wrote (2625)	11/5/1997 11:00:00 AM
From: tommysdad	Read Replies (2) \| Respond to of 6136

If you don't mind a response from a proud, card-carrying member of the Little Punk Patrol -- A search of a few of my favorite databases revealed no recent news about AG3340. Results of a Phase I study were reported in April: agouron.com Steven Bender, a chemist on the MMP project, gave a nice talk describing the discovery of AG3340 at the American Chemical Society meeting in Las Vegas in September which was very positive, but there was no new quantitative biological data presented ("initial studies have been encouraging"). I believe the abstract you posted is the most recent info on efficacy of AG3340 in any species.